Hexose 6-phosphate dehydrogenase (H6PD) and corticosteroid metabolism

Perrin C. White, Daniela Rogoff, D. Randy McMillan, Gareth G. Lavery

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Cortisone or (in rodents) 11-dehydrocorticosterone are reduced to cortisol or corticosterone, respectively, by the oxo-reductase activity of 11β-hydroxysteroid dehydrogenase type 1 (11-HSD1). This requires NADPH, generated by hexose-6-phosphate dehydrogenase (H6PD), a component of the pentose phosphate pathway. H6PD is located along with 11-HSD1 in the lumen of the endoplasmic reticulum (ER). Increasing or decreasing expression levels of H6PD in cultured cells has corresponding effects on the reductase activity of 11-HSD1. Mice carrying a targeted mutation in H6PD have drastically decreased 11-HSD1 oxo-reductase activity, but their 11-dehydrogenase activity is increased. They have many phenotypic features in common with mice carrying a mutation of 11-HSD1 itself. Polymorphisms in both H6PD and 11-HSD1 were originally identified in patients with apparent cortisone reductase deficiency (who have signs of hyperandrogenism and decreased urinary excretion of cortisol versus cortisone metabolites). However, these polymorphisms do not have detectable biochemical or physiologic effects when prospectively ascertained.

Original languageEnglish (US)
Pages (from-to)89-92
Number of pages4
JournalMolecular and Cellular Endocrinology
Volume265-266
Issue numberSUPPL.
DOIs
StatePublished - Feb 2007

Fingerprint

11-beta-Hydroxysteroid Dehydrogenases
Metabolism
Adrenal Cortex Hormones
Oxidoreductases
Cortisone
Polymorphism
Cortisone Reductase
Hydrocortisone
Hyperandrogenism
Pentoses
Pentose Phosphate Pathway
Mutation
Corticosterone
Metabolites
NADP
Endoplasmic Reticulum
galactose-6-phosphate dehydrogenase
Cultured Cells
Rodentia
Phosphates

Keywords

  • 11β-Hydroxysteroid dehydrogenase
  • Corticosterone
  • Cortisol
  • Endoplasmic reticulum
  • Pentose phosphate pathway
  • Polycystic ovarian syndrome

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Hexose 6-phosphate dehydrogenase (H6PD) and corticosteroid metabolism. / White, Perrin C.; Rogoff, Daniela; McMillan, D. Randy; Lavery, Gareth G.

In: Molecular and Cellular Endocrinology, Vol. 265-266, No. SUPPL., 02.2007, p. 89-92.

Research output: Contribution to journalArticle

White, Perrin C. ; Rogoff, Daniela ; McMillan, D. Randy ; Lavery, Gareth G. / Hexose 6-phosphate dehydrogenase (H6PD) and corticosteroid metabolism. In: Molecular and Cellular Endocrinology. 2007 ; Vol. 265-266, No. SUPPL. pp. 89-92.
@article{ebc1108b160143c9bb5827c7a64dab89,
title = "Hexose 6-phosphate dehydrogenase (H6PD) and corticosteroid metabolism",
abstract = "Cortisone or (in rodents) 11-dehydrocorticosterone are reduced to cortisol or corticosterone, respectively, by the oxo-reductase activity of 11β-hydroxysteroid dehydrogenase type 1 (11-HSD1). This requires NADPH, generated by hexose-6-phosphate dehydrogenase (H6PD), a component of the pentose phosphate pathway. H6PD is located along with 11-HSD1 in the lumen of the endoplasmic reticulum (ER). Increasing or decreasing expression levels of H6PD in cultured cells has corresponding effects on the reductase activity of 11-HSD1. Mice carrying a targeted mutation in H6PD have drastically decreased 11-HSD1 oxo-reductase activity, but their 11-dehydrogenase activity is increased. They have many phenotypic features in common with mice carrying a mutation of 11-HSD1 itself. Polymorphisms in both H6PD and 11-HSD1 were originally identified in patients with apparent cortisone reductase deficiency (who have signs of hyperandrogenism and decreased urinary excretion of cortisol versus cortisone metabolites). However, these polymorphisms do not have detectable biochemical or physiologic effects when prospectively ascertained.",
keywords = "11β-Hydroxysteroid dehydrogenase, Corticosterone, Cortisol, Endoplasmic reticulum, Pentose phosphate pathway, Polycystic ovarian syndrome",
author = "White, {Perrin C.} and Daniela Rogoff and McMillan, {D. Randy} and Lavery, {Gareth G.}",
year = "2007",
month = "2",
doi = "10.1016/j.mce.2006.12.022",
language = "English (US)",
volume = "265-266",
pages = "89--92",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL.",

}

TY - JOUR

T1 - Hexose 6-phosphate dehydrogenase (H6PD) and corticosteroid metabolism

AU - White, Perrin C.

AU - Rogoff, Daniela

AU - McMillan, D. Randy

AU - Lavery, Gareth G.

PY - 2007/2

Y1 - 2007/2

N2 - Cortisone or (in rodents) 11-dehydrocorticosterone are reduced to cortisol or corticosterone, respectively, by the oxo-reductase activity of 11β-hydroxysteroid dehydrogenase type 1 (11-HSD1). This requires NADPH, generated by hexose-6-phosphate dehydrogenase (H6PD), a component of the pentose phosphate pathway. H6PD is located along with 11-HSD1 in the lumen of the endoplasmic reticulum (ER). Increasing or decreasing expression levels of H6PD in cultured cells has corresponding effects on the reductase activity of 11-HSD1. Mice carrying a targeted mutation in H6PD have drastically decreased 11-HSD1 oxo-reductase activity, but their 11-dehydrogenase activity is increased. They have many phenotypic features in common with mice carrying a mutation of 11-HSD1 itself. Polymorphisms in both H6PD and 11-HSD1 were originally identified in patients with apparent cortisone reductase deficiency (who have signs of hyperandrogenism and decreased urinary excretion of cortisol versus cortisone metabolites). However, these polymorphisms do not have detectable biochemical or physiologic effects when prospectively ascertained.

AB - Cortisone or (in rodents) 11-dehydrocorticosterone are reduced to cortisol or corticosterone, respectively, by the oxo-reductase activity of 11β-hydroxysteroid dehydrogenase type 1 (11-HSD1). This requires NADPH, generated by hexose-6-phosphate dehydrogenase (H6PD), a component of the pentose phosphate pathway. H6PD is located along with 11-HSD1 in the lumen of the endoplasmic reticulum (ER). Increasing or decreasing expression levels of H6PD in cultured cells has corresponding effects on the reductase activity of 11-HSD1. Mice carrying a targeted mutation in H6PD have drastically decreased 11-HSD1 oxo-reductase activity, but their 11-dehydrogenase activity is increased. They have many phenotypic features in common with mice carrying a mutation of 11-HSD1 itself. Polymorphisms in both H6PD and 11-HSD1 were originally identified in patients with apparent cortisone reductase deficiency (who have signs of hyperandrogenism and decreased urinary excretion of cortisol versus cortisone metabolites). However, these polymorphisms do not have detectable biochemical or physiologic effects when prospectively ascertained.

KW - 11β-Hydroxysteroid dehydrogenase

KW - Corticosterone

KW - Cortisol

KW - Endoplasmic reticulum

KW - Pentose phosphate pathway

KW - Polycystic ovarian syndrome

UR - http://www.scopus.com/inward/record.url?scp=33847019963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847019963&partnerID=8YFLogxK

U2 - 10.1016/j.mce.2006.12.022

DO - 10.1016/j.mce.2006.12.022

M3 - Article

VL - 265-266

SP - 89

EP - 92

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

IS - SUPPL.

ER -